GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2009

Enzo Teams Up with NIH National Eye Institute for Clinical Trial with Optiquel

  • Enzo Biochem signed a cooperative R&D agreement with the NIH’s National Eye Institute, centered on carrying out a proof-of-concept clinical trial of Optiquel™, Enzo’s oral therapeutic for chronic autoimmune uveitis.

    Enzo will supply the compound and fund a portion of the studies. The agreement with the National Eye Institute also covers nonclinical research into the use of compounds to enhance the immune-mediated oral tolerance response to specific antigens.

    Enzo says that this work may have applications across its whole immune regulation platform including its Crohn’s disease candidate, Alequel™, and EGS21™, which is in development for treating nonalcoholic steatohepatitis. Enzo most recently reported positive results from a Phase II trial with Alequel in patients with moderate-to-severe Crohn’s disease.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?